23 results about "Enterococcus bacteria" patented technology

A general formula for lysins based on which the activity and functionality are further screened and 24 lysins are identified and further investigated, nine of which are characterized. These lysins exhibit potent bactericidal activity, capable of lysing multiple species of Staphylococcus, Streptococcus, and / or Enterococcus; demonstrate robust environmental resistance and stability, retaining activity under varying temperatures, NaCl concentrations, pH levels, and in immune serum; and effectively treat localized and systemic infections. These lysins and their variants are promising as antimicrobial agents for eradicating bacteria, preventing bacterial infections, or treating bacterial infections (caused by genera Staphylococcus, Streptococcus, and / or Enterococcus).

The application discloses a brain hemorrhage prognosis improvement method based on intestinal flora regulation and relates to the technical field of intestinal microecology.The application comprises the following steps: detecting feces, starting intervention if the enterococcus abundance and neuroinflammatory metabolic markers exceed the standard, stopping the use of conventional nutrient solution, perfusing a special component containing sugar analogs, blocking the energy uptake of enterococcus, simultaneously providing a carbon source for beneficial bacteria, synchronously perfusing a microsphere suspension containing a molecular capture function, adsorbing and fixing proinflammatory metabolic waste in the intestinal tract, blocking the blood entry of the proinflammatory metabolic waste, perfusing live bacteria with different functions three times in time sequence, sequentially completing the acidification of the environment, constructing a bacterial membrane barrier and repairing the intestinal epithelium, and re-detecting after each round of intervention, selecting the maintenance period or adjusting the intensity and then recycling according to the decrease of enterococcus and markers.The application can limit the competitive advantage of enterococcus in the utilization of carbon sources after brain hemorrhage by sequentially implementing competitive inhibition of the phosphotransferase system and multi-species ecological niche occupation.

This invention belongs to the field of peptide drugs, specifically relating to an anti-drug-resistant bacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 9I and 16F replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-11. Compared to the template peptide PL-0, the stapling peptide PL-11 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

This invention belongs to the field of peptide drugs, specifically relating to an anti-drug-resistant bacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 6V and 13V replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-10. Compared to the template peptide PL-0, the stapling peptide PL-10 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

This invention belongs to the field of peptide drugs, specifically relating to an antibacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 13V and 20V replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-13. Compared to the template peptide PL-0, the stapling peptide PL-13 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

Provided is a pharmaceutical composition for preventing or treating benign prostatic hyperplasia or alopecia, comprising lactic acid bacteria of Enterococcus genus as an active ingredient. The pharmaceutical composition of the present invention can replace the conventional therapeutic agents against treating benign prostatic hyperplasia or alopecia, such as finasteride or dutasteride. In particular, by introducing heat-killed probiotics of Enterococcus faecalis, the effect of preventing or treating benign prostatic hyperplasia or alopecia can be further enhanced.

The application belongs to the field of polypeptide drugs, and particularly relates to an antibacterial polypeptide and application thereof in pharmacy. The application takes Rink amide MBHA amino resin as a solid phase carrier, and modifies and transforms according to a template polypeptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 amino acid sequence, wherein amino acid residues 19G and 26N are replaced by R8 and S5, to obtain a target stapled peptide PL-16. The stapled peptide PL-16 can significantly improve the antibacterial activity on Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis and Staphylococcus epidermidis relative to the template polypeptide PL-0.

The present invention relates to a novel peptide comprising the amino acid sequence of SEQ ID NO: 1, and an antibacterial composition comprising same. The peptide of the present invention, which is an Enterococcus lactis-derived antibacterial peptide APP101, has specific antibacterial activity against periodontitis-causing bacteria including Porphyromonas gingivalis, Fusobacterium nucleatum, Enterococcus faecalis, Streptococcus parasanguinis, and Streptococcus salivarius, and has stability against proteases, pH, and salt concentrations. The antimicrobial composition of the present invention can be usefully employed for the prevention or treatment of periodontitis.

Methods comprising obtaining a biological sample and extracting nucleic acids from it are disclosed. The methods process the nucleic acids for DNA sequencing and identify in the DNA sequencing data a plurality of amplicon sequence variants (ASV). The methods record the relative abundance of each ASV and classify, using a machine learning algorithm, each ASV according to one of a set of taxonomies. The set of taxonomies includes a pathobiont bacteria subset consisting of genus level groups Eggerthella group, Ruminococcus torques group, Ruminococcus gnavus group, Coprobacillus group, Streptococcus group, Bilophila group, Actinomyces group, Desulfovibrio group, Atopobiaceae group, Veillonella group, Enterococcus group, Escherichia-Shigella group, Campylobacter group, Enterobacteriaceae group, and Fusobacterium group. Based on the relative abundance of the ASV classified as pathobiont bacteria, a numerical indication of the health of the subject is calculated. Based on the numerical indication, the methods deliver to the subject a customized intervention.

The application discloses a bacteriocin expressed by bacillus subtilis WB800N and application thereof. The original sequence of the bacteriocin is a bacteriocin PA from bacillus polymyxa, the nucleotide sequence of the bacteriocin PA is shown as SEQ ID NO:1, and the amino acid sequence is shown as SEQ ID NO:2. The bacteriocin PA coding gene is modified by a tag and optimized by a codon to obtain a bacteriocin PFH, the nucleotide sequence of the bacteriocin PFH is shown as SEQ ID NO:3, and the amino acid sequence is shown as SEQ ID NO:4. The bacteriocin PFH expressed by the bacillus subtilis WB800N has a good bacteriostatic effect on gram-positive bacteria such as streptococcus suis, enterococcus faecium, staphylococcus aureus and bacillus subtilis, and has a wide application prospect in the development of a new type of replacement product for infection treatment and a feed antibacterial peptide.

This invention discloses a chromium (VI)-resistant Enterococcus faecium, its isolation method, and its applications in the field of microbial technology. This chromium (VI)-resistant Enterococcus faecium, classified and named Enterococcus faecium, was deposited on October 24, 2025, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC NO.36330. The chromium (VI)-resistant Enterococcus faecium isolated by this invention can survive in high-concentration chromium (VI) environments and has a strong adsorption effect on hexavalent chromium, reducing the residue and bioaccumulation of hexavalent chromium in feed, thereby mitigating its toxicity to poultry.

This invention provides biomarkers, kits, and drugs for predicting or diagnosing childhood sepsis. The biomarkers include *Enterococcus raffinis*. Based on statistical analysis, machine learning modeling results, and independent cohort validation, this invention found significant enrichment of *Enterococcus raffinis* and sulfated bile acid derivatives in pediatric sepsis patients. In vitro and in vivo experiments confirmed that symbiotic gut microbiota (especially *Enterococcus raffinis*) produces at least 80% of its total DCA-3S production, highlighting the dominant role of the gut microbiota in DCA-3S biosynthesis.

The present application relates to the technical field of microorganism, and especially relates to a kind of Enterococcus durans C24, probiotic agent and application thereof.The present application provides Enterococcus durans C24, and its preservation number is CGMCC No.33995.The strain has broad-spectrum antibacterial activity, can inhibit Salmonella enteritidis, Salmonella pullorum and Salmonella typhimurium, has no hemolytic activity, and has good stress resistance, can survive in gastrointestinal environment, and also has high biological safety, and is expected to be used for clinical prevention and control of salmonellosis.

The present invention relates to antibiotic-resistant bacteria, and to the prevention or treatment of infections of drug-resistant pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE) and / or vancomycin-resistant Enterococcus (VRE). In particular, the invention relates to the treatment or prevention of colonisation of CRE and / or VRE in the gastrointestinal (GI) tract, before they cause invasive infections, for example in the blood. The invention provides novel formulations, pharmaceutical compositions and methods of using them to prevent or treat CRE and / or VRE infections or intestinal colonisations thereof.

A method of treatment and use of probiotic compositions in treatment of weight loss-related conditions in wasting, and cachexia, includes the steps of administering a probiotic composition to a subject deemed in need of such treatment wherein the composition includes at least two bacteria, each preferably selected from a different genus, the genera preferably selected from the group Lactobacillus spp, Enterococcus spp, and Bifidobacterium spp, and a probiotic composition for use in treatment of a subject having a weight loss-related condition wherein the composition includes at least two bacteria, each preferably selected from a different genus, the genera preferably selected from the group Lactobacillus spp, Enterococcus spp, and Bifidobacterium spp.

This invention belongs to the field of synthetic biology and discloses tetracycline compounds modified with a polysaccharide group at the C8 position, their biosynthetic methods, and applications. The tetracycline compounds with a polysaccharide group modification at the C8 position provided by this invention have a novel structure; the trisaccharide and hexasaccharide groups present at the C8 position are not found in known tetracycline natural products or tetracycline skeleton antibiotics. The biosynthetic method involves using a polysaccharide group derived from *Streptomyces rubrum*. ech Gene clusters, in which mis This invention expresses the gene cluster in the *Streptomyces micranthum* host, fully utilizing the different biosynthetic enzymes contained in two similar but different tetracycline natural product biosynthetic gene clusters to synthesize novel compounds that neither host bacterium can synthesize. These compounds exhibit significant inhibitory activity against *Staphylococcus aureus*, *Enterococcus faecalis*, and *Enterococcus faecium*. This invention provides new candidate compounds for the innovative development of tetracycline-based antibacterial drugs and is of great significance to the development of microbial drug resources.

The application belongs to the field of polypeptide drugs, and particularly relates to an antibacterial polypeptide and application thereof. The Rink amide MBHA amino resin is used as a solid phase carrier, and a template polypeptide raniseptin PL: Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 amino acid sequence is modified and reformed. On the basis of reserving key amino acid residues, S5 and R8 are respectively used to replace original amino acids at i, i+4 and i, i+7 amino acid positions, so that a target stapled peptide is obtained. The stapled peptide can significantly improve the antibacterial activity on Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis and Staphylococcus epidermidis relative to the template polypeptide PL-0.

The present application belongs to the technical field of medicine, and particularly relates to a probiotic composition, a fermented traditional Chinese medicine composition and application. The probiotic composition with xanthine oxidase inhibiting effect comprises the following components: Lactobacillus plantarum, Enterococcus faecium 1 and Enterococcus faecium 2. The Lactobacillus plantarum has a preservation number of CGMCC 1.557, the Enterococcus faecium 1 has a preservation number of CICC 6078, and the Enterococcus faecium 2 has a preservation number of CGMCC 1.130. The present application utilizes the uric acid method to determine that the Lactobacillus plantarum, the Enterococcus faecium 1 and the Enterococcus faecium 2 have a strong inhibiting effect, and after the three kinds of bacteria are mixed, the inhibiting rate is 65%, which reflects that the three kinds of bacteria strains have good synergism in inhibiting the xanthine oxidase effect.

The present application relates to a kind of enterococcus faecalis and its application.The enterococcus faecalis is preserved in China Microorganism Culture Collection Center on September 24, 2025, and the preservation number is CGMCC No.36054.The enterococcus faecalis CGMCC No.36054 has strong antioxidant capacity, and has strong tolerance to gastrointestinal fluid.In addition, the bacteria have strong diacetyl production capacity, and the diacetyl content in yogurt can be greatly improved by inoculating the bacteria after ultrasonic treatment, and other flavor substances in yogurt are also enriched.

This invention belongs to the field of microbiology, specifically relating to the application of albizophenolic compounds. These compounds inhibit pathogenic bacteria such as Salmonella, Mycobacterium smegmatis, Enterococcus faecalis, and Staphylococcus aureus, and inhibit the growth of human lung cancer cells and human breast cancer cells, exhibiting bactericidal and anticancer activities. They are suitable for developing products for everyday household use, medical care, and animal husbandry, with broad prospects for industrial application.

The application relates to the technical field of bacteriophages, in particular to a Enterococcus faecalis bacteriophage and a composition and kit formed by the same. The Enterococcus faecalis bacteriophage is Enterococcus faecalis bacteriophage P35AEFLN26, the classification name of which is Enterococcus faecalis phage P35AEFLN26, the preservation number is CCTCC NO: M 2025336, and the Enterococcus faecalis bacteriophage has the nucleotide sequence shown in SEQ ID No. 1. The bacteriophage has a wide host range, a wide acid and alkali tolerance range, certain resistance to chloroform and diethyl ether, can maintain high activity while lysing target bacteria, has excellent thermal stability, can adapt to the application requirements of multiple temperature nodes in production, and has the potential to be applied as a biosensor.

The present application relates to the technical field of microorganism, in particular to a strain of Enterococcus hirae QHBMA068, a composition containing the same and use thereof.The Enterococcus hirae is Enterococcus hirae QHBMA068, the preservation number of which is CCTCC NO: M 20252987, and it is preserved in China Center for Type Culture Collection.The composition contains at least one of Pediococcus acidilactici and a culture of the strain.The composition is used for preparing a composition for feed fermentation.The present application has the following advantages: (1) high efficiency in degrading mycotoxins; (2) good probiotic properties, strong growth performance, strong acid tolerance, bile salt tolerance and osmotic pressure tolerance; (3) good hydrophobicity and self-aggregation performance; and (4) high safety.